Crescent Biopharma (CBIO) 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA summary

Company strategy and portfolio overview

• Focused on building a next-generation oncology biotech with two main strategies: IO bispecifics and ADCs, aiming for best-in-class therapies for cancer patients.

• Four clinical studies across three programs will be initiated this year, setting up a data-rich 2027.

• Leveraging a partnership with Kelun-Biotech for data generation and combination studies, especially with ADCs.

• Well-financed to reach key milestones and execute on planned studies through 2026.

CR-001 program insights

• CR-001 is designed to replicate and improve upon ivonescimab, with a proprietary modification allowing higher concentration manufacturing.

• Preclinical data show comparable pharmacology and anti-tumor activity to ivonescimab.

• ASCEND, a global phase I trial, is underway, focusing on multiple tumor types including lung, GI, and gynecological cancers.

• Initial comprehensive data, including safety, PK, and anti-tumor activity, expected in Q1 2027.

• Expansion cohorts will provide efficacy data in first-line non-small cell lung cancer and other tumor types.

ADC and combination therapy strategy

• Matrix portfolio approach combines best-in-class and first-in-class opportunities across IO bispecifics and ADCs.

• Partnership with Kelun-Biotech enables access to a broad ADC pipeline, including integrin beta-6 topo ADC (CR-003) and potential combinations with CR-001.

• Data from Kelun’s sac-TMT ADC and pembrolizumab combinations are closely watched for safety and efficacy insights relevant to CR-003.

• CR-003 is optimized for internalization, safety, and efficacy, targeting integrin beta-6, which is overexpressed in multiple solid tumors.